18 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Regeneron's Cocktail for Coronavirus Selected for RECOVERY Study http://www.zacks.com/stock/news/1058574/regenerons-cocktail-for-coronavirus-selected-for-recovery-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1058574 Sep 15, 2020 - Regeneron's (REGN) investigational anti-viral antibody cocktail, REGN-COV2, has been selected for evaluation in the RECOVERY study.
Eli Lilly and Co (LLY) Presents at Morgan Stanley Global Healthcare Broker Conference Call - (Transcript) https://seekingalpha.com/article/4374808-eli-lilly-and-co-lly-presents-morgan-stanley-global-healthcare-broker-conference-call?source=feed_sector_healthcare Sep 16, 2020 -
Lilly Drug Gets Fast Track to Improve Heart Attack Outcome http://www.zacks.com/stock/news/1059134/lilly-drug-gets-fast-track-to-improve-heart-attack-outcome?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1059134 Sep 16, 2020 - Lilly's (LLY) EMPACT-MI study is part of Jardiance's ENPOWER clinical program, which is studying the impact of Jardiance on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions.
No Rate Hike Until 2023: Here's How to Play With ETFs http://www.zacks.com/stock/news/1060092/no-rate-hike-until-2023-heres-how-to-play-with-etfs?cid=CS-ZC-FT-etf_news_and_commentary-1060092 Sep 18, 2020 - As widely expected, the Fed held interest rates steady at a near-zero level in its latest meeting.
Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals http://www.zacks.com/stock/news/1060523/pharma-stock-roundup-azn-lly-pfes-coronavirus-updates-mrks-new-cancer-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-1060523 Sep 18, 2020 - AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.
Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody http://www.zacks.com/stock/news/1060534/sorrento-gets-fda-nod-for-phase-i-study-on-coronavirus-antibody?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1060534 Sep 18, 2020 - Sorrento (SRNE) receives an FDA clearance to begin a phase I study on STI-1499 (COVI-GUARD) for treating hospitalized COVID-19 patients. Shares rise.
Lilly's Olumiant Gets CHMP Nod for Eczema Label Expansion http://www.zacks.com/stock/news/1061199/lillys-olumiant-gets-chmp-nod-for-eczema-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1061199 Sep 21, 2020 - Eli Lilly's (LLY) label expansion application for Olumiant to include atopic dermatitis in Europe patients gets CHMP recommendation for approval in Europe.
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib http://www.zacks.com/stock/news/1062512/redhill-gets-nod-in-brazil-for-coronavirus-study-on-opaganib?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1062512 Sep 23, 2020 - The Brazilian Health Regulatory Agency okays RedHill's (RDHL) to conduct a phase II/III study on opaganib for treating patients with severe COVID-19 infection and pneumonia. Stock up.

Pages: 12

<Page 2